Proove Biosciences Will Exhibit Research at the American Society of Anesthesiology’s 2014 Annual Meeting

Share Article

Proove Biosciences will exhibit their PROUD Study on the relationship between genetics and popular prescription pain medications

Proove will be presenting their new PROUD Study at the American Society of Anesthesiology’s 2014 Annual Meeting in New Orleans on October 11th-15th. The five-day event attracts upwards of 15,000 attendees from around the world seeking to learn about the latest trends in science and technology related to the practice of anesthesiology.

Proove has been presenting research and data at industry conferences across the country this past year, demonstrating the value and innovation their genetic testing creates in the field of pain medicine. Their most recent research, the PROUD Study, which focuses on the relationship between genetics and a patient’s reaction to Oxycodone and Benzodiepine, will be exhibited at the ASA’s meeting this week. Proove will be presenting in order to educate physician-anesthesiologists and leaders in the specialty on how analyzing patients’ genetic profile can help them better address their pain treatments.

“The American Society of Anesthesiologists is a premier educational and scientific association of leading physicians who are intimately involved in treatment of patients’ pain and pain management. The ASA’s Annual Meeting is a great forum to demonstrate how Proove’s research and genetic suite of tests has been helping physicians ensure they are prescribing the safest and most efficient treatments,” stated Brian Meshkin, CEO or Proove Biosciences.

About Proove Biosciences

Our mission is to change the future of medicine by providing proof to improve healthcare decisions. We envision a future when clinicians will know how patients are likely to respond to medications before writing a prescription. We believe genetic testing can provide such knowledge: Using a simple cheek swab, Proove performs proprietary genetic tests in its CLIA-certified laboratory. Healthcare providers use the results to evaluate how their patients will metabolize medications, and to screen for the likelihood of medication misuse.

Founded in 2009 with offices in Southern California and the Baltimore-Washington metropolitan area, Proove Biosciences is the leader in genetics-related personalized pain medicine research with hundreds of clinical research sites across the U.S. For more information, please visit http://www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Nicole McMillan
Proove Biosciences
+1 855-776-6832 Ext: 716
Email >
@proovebio
Follow >
Proove Biosciences, Inc.
since: 01/2012
Like >
Visit website